arXiv 2509.04939
The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors
By Linh Nguyen Phuong, Frederic Fina, et al.
Published 2025-09-05
Mindmap
Browse the paper's core ideas, clusters, and relationships in a structured outline.
Background: Many advanced cancer patients experience progression under immune-checkpoint inhibitors (ICIs). Circulating cell-free DNA (cfDNA) size profiles offer a promising noninvasive multi-cancer approach to monitor and predict immunotherapy response. Methods: In the SChISM (Size CfDNA Immunotherapy Signature Monitoring) study (NCT05083494), pre-treatment plasmatic cfDNA size profiles from 126 ICI-treated advance…